FluoGuide realises the first price trigger
Through a private placement at market price, FluoGuide raises SEK 60M to initiate planned Phase II trials and trigger the
19. June 2024
Through a private placement at market price, FluoGuide raises SEK 60M to initiate planned Phase II trials and trigger the
NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. Last week, the KPHC
The Mobility sector is the one and only this year performing exceptionally well with a 38% return year-to-date. Clean Motion
Curasight is off to a great start in 2024 with a milestone payment from Curium. After a whirlwind 2023 with
Curasight has received positive results from a Phase 2 study of uTRACE in aggressive brain cancer, validating the technology and
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.